Success Metrics

Clinical Success Rate
81.4%

Based on 35 completed trials

Completion Rate
81%(35/43)
Active Trials
12(16%)
Results Posted
37%(13 trials)
Terminated
8(11%)

Phase Distribution

Ph phase_1
9
12%
Ph not_applicable
21
28%
Ph phase_4
1
1%
Ph phase_3
2
3%
Ph phase_2
8
11%

Phase Distribution

9

Early Stage

8

Mid Stage

3

Late Stage

Phase Distribution41 total trials
Phase 1Safety & dosage
9(22.0%)
Phase 2Efficacy & side effects
8(19.5%)
Phase 3Large-scale testing
2(4.9%)
Phase 4Post-market surveillance
1(2.4%)
N/ANon-phased studies
21(51.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.1%

35 of 46 finished

Non-Completion Rate

23.9%

11 ended early

Currently Active

12

trials recruiting

Total Trials

76

all time

Status Distribution
Active(15)
Completed(35)
Terminated(11)
Other(15)

Detailed Status

Completed35
unknown15
Recruiting9
Terminated8
Not yet recruiting3
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
76
Active
12
Success Rate
81.4%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (22.0%)
Phase 28 (19.5%)
Phase 32 (4.9%)
Phase 41 (2.4%)
N/A21 (51.2%)

Trials by Status

not_yet_recruiting34%
withdrawn34%
recruiting912%
active_not_recruiting34%
completed3546%
unknown1520%
terminated811%

Recent Activity

Clinical Trials (76)

Showing 20 of 76 trialsScroll for more
NCT05822791

Differences in ECG- vs. proLonged cardIac MonItor-DeTected Atrial Fibrillation in STROKE Patients (DELIMIT AF-STROKE)

Active Not Recruiting
NCT07785531

Risk Factors, Etiology and Predictable Outcomes With Risk Stratification Scores in Acute Heart Failure Patients

Not Yet Recruiting
NCT04896073Phase 2

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

Completed
NCT05286827Phase 2

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Terminated
NCT02769962Phase 1

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Terminated
NCT07717450Phase 3

Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

Not Yet Recruiting
NCT07715474

ALIGN-ACS Pilot Study

Active Not Recruiting
NCT03436745Phase 1

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Terminated
NCT05185947Phase 2

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

Completed
NCT06602934Not Applicable

Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia

Recruiting
NCT07460154Not Applicable

Structured Review: To Optimise Management and Prevent Harm in COPD

Recruiting
NCT06292377Not Applicable

Better Understanding of Fatigue After STroke

Recruiting
NCT02780128Phase 1

Next Generation Personalized Neuroblastoma Therapy

Terminated
NCT05573633Not Applicable

Diagnosis of Postoperative Atrial Fibrillation by a Smartwatch

Recruiting
NCT04316650Not Applicable

Study of Maintenance of the Efficiency and Adverse Effects of Pharmacological Treatments in Sex Offenders With Paraphilia

Withdrawn
NCT04294641Phase 2

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Completed
NCT07364656Not Applicable

Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors

Not Yet Recruiting
NCT04167033Not Applicable

Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QTIOP)

Recruiting
NCT05918055Phase 1

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Terminated
NCT05148234Phase 1

BMS-986253 in Myelodysplastic Syndromes

Terminated

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
76